Organophosphates are irreversible acetylcholinesterase inhibitors. Atropine is a muscarinic antagonist that competitively blocks the effects of excess acetylcholine at muscarinic receptors, treating symptoms like bradycardia, salivation, and bronchospasm. However, it has no effect on nicotinic receptors (responsible for muscle fasciculations and weakness). Pralidoxime is a cholinesterase reactivator that removes the organophosphate from the enzyme, restoring its function. It must be given early, before the bond 'ages'.

The patient is presenting with classic anticholinergic (antimuscarinic) toxicity, often remembered by the mnemonic 'hot as a hare, blind as a bat, dry as a bone, red as a beet, mad as a hatter.' The toxins in Atropa belladonna, such as atropine and scopolamine, are potent competitive antagonists of muscarinic cholinergic receptors, leading to inhibition of parasympathetic functions.

Oxybutynin is an antimuscarinic agent that blocks M3 receptors on the detrusor muscle, causing it to relax and increasing bladder capacity. However, it also blocks muscarinic receptors elsewhere in the body, leading to classic anticholinergic side effects. These include dry mouth (xerostomia) due to blockade of M3 receptors on salivary glands, constipation, blurred vision, and confusion, especially in the elderly.

Phenylephrine is a selective alpha-1 adrenergic agonist. Activation of alpha-1 receptors on vascular smooth muscle causes potent vasoconstriction, which increases systemic vascular resistance (SVR) and, consequently, blood pressure. It has minimal effect on beta receptors, so it does not directly increase heart rate or contractility and may cause a reflex bradycardia.

Clonidine is a centrally acting alpha-2 adrenergic agonist. It stimulates alpha-2 receptors in the brainstem (specifically the nucleus tractus solitarii), which inhibits presynaptic release of norepinephrine. This leads to a decrease in central sympathetic outflow, reducing heart rate, cardiac output, and peripheral vascular resistance, thereby lowering blood pressure.

Dobutamine is a synthetic catecholamine that is primarily a beta-1 adrenergic agonist. Stimulation of beta-1 receptors in the heart leads to a significant increase in myocardial contractility (positive inotropy) and, to a lesser extent, heart rate. This improves cardiac output and organ perfusion in cardiogenic shock. Dobutamine also has weak beta-2 agonist activity, which can cause mild vasodilation and a decrease in systemic vascular resistance (afterload).

Albuterol is a short-acting beta-2 selective adrenergic agonist used for bronchodilation. However, at higher doses or with frequent use, its selectivity decreases. The tremor (shaky hands) results from stimulation of beta-2 receptors in skeletal muscle. The tachycardia (heart racing) occurs due to stimulation of both beta-2 receptors present in cardiac tissue and some cross-reactivity with cardiac beta-1 receptors at higher doses.

Prazosin is an alpha-1 adrenergic antagonist. It blocks alpha-1 receptors on both arterial and venous smooth muscle, causing vasodilation and a decrease in blood pressure. A well-known adverse effect, particularly with the first dose or after a dose increase, is orthostatic hypotension. This occurs because the blockade of venous alpha-1 receptors prevents the normal vasoconstrictor response needed to maintain blood pressure upon standing.

Carvedilol (and labetalol) are non-selective beta-blockers that also have alpha-1 blocking properties. In heart failure, the beta-1 blockade reduces the harmful effects of chronic sympathetic stimulation on the heart (e.g., remodeling, apoptosis). The alpha-1 blockade causes peripheral vasodilation, which reduces both preload and afterload, further decreasing the workload on the failing heart.

Scopolamine is a centrally acting antimuscarinic agent. It is particularly effective for motion sickness because it blocks muscarinic receptors in the vestibular system and the brainstem vomiting center. The side effects of drowsiness and dry mouth are due to its central and peripheral anticholinergic properties, respectively.